Drugs / GC022F
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04412174 | Jun 2020 → Dec 2022 | B-cell non-Hodgkin lymphoma | Hebei Yanda Ludaopei Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT04129099 | Oct 2019 → Sep 2020 | B-cell acute lymphoblastic leukemia | Hebei Yanda Ludaopei Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-12-09 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Results Gracell Announces Progressive Outcomes from Multiple Human Clinical Trials to Investigate FasTCAR and Dual CAR Cell Platform Technologies gracellbio.com ↗
Dual CAR-BCMA-19 (GC012) demonstrates excellent tumor eliminating capabilities in preclinical study aligned with encouraging safety and efficacy data for r/r MM treatment |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-12-09 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Gracell Announces Progressive Outcomes from Multiple Human Clinical Trials to Investigate FasTCAR and Dual CAR Cell Platform Technologies gracellbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC022F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04412174 ↗ |
| Modality | Cell therapy | “CAR-T cell immunotherapy” NCT04129099 ↗ |
| Target | CD19 | “targeted CD19” NCT04129099 ↗ |
| Target | CD22 | “targeted CD19 and CD22” NCT04129099 ↗ |